A research agenda for malaria eradication: drugs
| Autor: | R Chandra, Quique Bassat, Janice Culpepper, François Nosten, J Nájera, Dyann F. Wirth, J Pottage, Christopher V. Plowe, Ramanan Laxminarayan, Pascal Ringwald, C Marzetta, Steve A. Ward, Pedro L. Alonso, Peter G. Kremsner, MacArthur, Mark M. Fukuda, R. Sinden, Theonest K. Mutabingwa, Ivo Mueller, Alan J. Magill, Y Yuthavong, Jessica Milman, Nicholas J. White, Thomas E. Wellems, Regina Rabinovich, Abdoulaye Djimde, Rhoel R. Dinglasan, C Ohrt, Dennis Shanks, Ric N. Price, Stephan Duparc, Fred Binka, K Duncan, Marcel Tanner, H Vial, Robert D. Newman, Solomon Nwaka, Shunmay Yeung, A. Serazin, Thomas G. Brewer, Timothy N. C. Wells, Myaing M. Nyunt |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Insecticides
Plasmodium Mosquito Control Plasmodium vivax Drug Resistance lcsh:Medicine Review Parasitemia Lactones Pregnancy Recurrence Mass treatment Pregnancy Complications Infectious Child health care economics and organizations media_common Travel biology Transmission (medicine) General Medicine humanities Artemisinins Aminoquinolines Female Drug Adult medicine.medical_specialty Asia media_common.quotation_subject macromolecular substances Antimalarials Malaria transmission Species Specificity Malaria elimination Anopheles Malaria Vaccines parasitic diseases medicine Animals Humans Intensive care medicine Contraindications Research lcsh:R Plasmodium falciparum social sciences biology.organism_classification medicine.disease Insect Vectors Malaria Glucosephosphate Dehydrogenase Deficiency Infectious Diseases/Neglected Tropical Diseases Immunology Africa Program Evaluation |
| Zdroj: | PLoS Medicine, Vol 8, Iss 1, p e1000402 (2011) PLoS Medicine |
| ISSN: | 1549-1277 |
| Popis: | The Malaria Eradication Research Agenda (malERA) Consultative Group on Drugs present a research and development agenda to ensure that appropriate drugs are available for use in malaria eradication. Antimalarial drugs will be essential tools at all stages of malaria elimination along the path towards eradication, including the early control or “attack” phase to drive down transmission and the later stages of maintaining interruption of transmission, preventing reintroduction of malaria, and eliminating the last residual foci of infection. Drugs will continue to be used to treat acute malaria illness and prevent complications in vulnerable groups, but better drugs are needed for elimination-specific indications such as mass treatment, curing asymptomatic infections, curing relapsing liver stages, and preventing transmission. The ideal malaria eradication drug is a coformulated drug combination suitable for mass administration that can be administered in a single encounter at infrequent intervals and that results in radical cure of all life cycle stages of all five malaria species infecting humans. Short of this optimal goal, highly desirable drugs might have limitations such as targeting only one or two parasite species, the priorities being Plasmodium falciparum and Plasmodium vivax. The malaria research agenda for eradication should include research aimed at developing such drugs and research to develop situation-specific strategies for using both current and future drugs to interrupt malaria transmission. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|